<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845946</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.187</org_study_id>
    <nct_id>NCT03845946</nct_id>
  </id_info>
  <brief_title>CLOUD-R HAE REGISTRY</brief_title>
  <acronym>CloudRHAE</acronym>
  <official_title>International Registry of Isolated Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5
      days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In
      this last location edema can be lethal causing asphyxia, in all other cases full recovery is
      complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of
      allergic origin. But there is a group of non-allergic angioedema that occur without hives and
      can be either hereditary or acquired. These angioedema are identified in some cases on the
      basis of etiology, in others are identified by the mediator and an overall classification of
      these forms of angioedema was published in 2014 as a result of a consent conference organized
      by the proponents of this registry. Being these forms of angioedema rare, there are not
      significative case studies inclusive of a high number of patients. This registry aims to
      collect in a single place a high number of subjects with recurring angioedema and without
      urticaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Grenoble center is the registry coordinator at the national level. It will contract
      directly with the Cloud R Company and will be in charge of coordinating the associated
      centers. It will therefore send the necessary documents for the good execution of the study,
      will ask each center to respect the current French regulatory, will organize and finance the
      set-up of the register in the associated centers.

      The coordinating center will also centralize requests for data, publications or creation of
      additional eCRF pages of associated centers. It will be able to organize a national
      scientific committee every 6 months. It will thus be the link between the French centers, the
      scientific committee of the registry and the company Cloud R.

      The coordinating center will also be responsible for enter and reliability of patient data
      from it center, as well as the associated centers.

      Role of associated centers Associated Centers will be responsible for capturing and data
      reliability of their patients in eCRF, they will also create a personal account for each
      patient so that it can download the application &quot;cloud R HAE carnet de suivi&quot;.

      Investigators referent patient will have validated at each visit or after contact with the
      patient crisis returned to the patient via it electronic diary.

      Associated Centers will keep informed twice a year the coordinator center of the state of
      inclusions in the register.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Demographic patient data</measure>
    <time_frame>5 years</time_frame>
    <description>Sexe and age of patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical characteristics</measure>
    <time_frame>5 years</time_frame>
    <description>summary of patient visit report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comorbidity</measure>
    <time_frame>5 years</time_frame>
    <description>additional diseases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angioedema diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>type of angiodema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angioedema diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>position of genetic mutation if applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angioedema diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>biology marker : C1inh, C4, C1q, anti C1inh</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angioedema diagnosis</measure>
    <time_frame>5 years</time_frame>
    <description>family history</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and severity of acute angioedema events</measure>
    <time_frame>5 years</time_frame>
    <description>start date</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and severity of acute angioedema events</measure>
    <time_frame>5 years</time_frame>
    <description>localization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and severity of acute angioedema events</measure>
    <time_frame>5 years</time_frame>
    <description>time before treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and severity of acute angioedema events</measure>
    <time_frame>5 years</time_frame>
    <description>time to resolution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and severity of acute angioedema events</measure>
    <time_frame>5 years</time_frame>
    <description>need access to hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in managing the acute angioedema event</measure>
    <time_frame>5 years</time_frame>
    <description>name</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in managing the acute angioedema event</measure>
    <time_frame>5 years</time_frame>
    <description>dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in managing the acute angioedema event</measure>
    <time_frame>5 years</time_frame>
    <description>date and time of acute treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in the prophylaxis of angioedema</measure>
    <time_frame>5 years</time_frame>
    <description>name</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in the prophylaxis of angioedema</measure>
    <time_frame>5 years</time_frame>
    <description>dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments used in the prophylaxis of angioedema</measure>
    <time_frame>5 years</time_frame>
    <description>start date</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>ANGIOEDEMA</condition>
  <arm_group>
    <arm_group_label>Hereditary angioedema type I/II</arm_group_label>
    <description>Hereditary angioedema with C1Inh deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acquired angioedema</arm_group_label>
    <description>Angioedema with acquired C1Inh deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug induced angioedema</arm_group_label>
    <description>Angioedema associated with ACEi used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mast cell induced angioedema</arm_group_label>
    <description>Spontaneous mast cell induced isolated angioedema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary angioedema with nC1Inh</arm_group_label>
    <description>Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>angioedema</intervention_name>
    <description>electronic tracking book</description>
    <arm_group_label>Acquired angioedema</arm_group_label>
    <arm_group_label>Drug induced angioedema</arm_group_label>
    <arm_group_label>Hereditary angioedema type I/II</arm_group_label>
    <arm_group_label>Hereditary angioedema with nC1Inh</arm_group_label>
    <arm_group_label>Mast cell induced angioedema</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with isolated angioedema without associated wheals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with isolated angioedema without associated wheals.

          -  Patients with hereditary angioedema with or without C1 deficiency.

          -  Major patient with consent (signature)

          -  Minor patient whose parents / legal guardians have given their consent (signature)

        Exclusion Criteria:

          -  Patient unable to give consent.

          -  Wheals with angioedema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>laurence bouillet</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>laurence bouilelt, MD, PhD</last_name>
    <phone>+33476765565</phone>
    <email>lbouillet@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Boccon-Gibod</last_name>
    <phone>+3347676767640</phone>
    <email>iboccon-gibod@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Isere</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Bouillet, MD, PhD</last_name>
      <phone>+33476765565</phone>
      <email>lbouillet@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>February 15, 2019</last_update_submitted>
  <last_update_submitted_qc>February 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

